Financial Highlights from Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a biopharmaceutical company committed to the creation and distribution of innovative critical care products, reported a successful financial quarter.
Significant Funding Achievements
During the recent quarter, the company raised a remarkable $12.5 million in gross financings. Notably, Citius Oncology secured an additional $9 million in funding in July to support pre-launch activities for LYMPHIR™, their new oncology product. This financial boost is critical as they prepare for a robust market introduction.
Strategic Transition and Launch Preparations
Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, expressed optimism about the company's capabilities to shift from a development phase to a fully integrated commercial entity. He stated the oncology subsidiary is making final preparations for the anticipated U.S. launch of LYMPHIR™ within the next quarter.
Operational Preparedness and Future Plans
In June, Citius completed a direct offering yielding $6 million, with the potential for additional financing up to $9.8 million from full warrant exercises. This raises the company's capital position, supporting various commercialization efforts, including large-scale manufacturing and distribution agreements.
Focus on Unmet Medical Needs
The development of LYMPHIR™ aims to provide new treatment options for cutaneous T-cell lymphoma, a disease lacking effective treatment alternatives. As Citius focuses on this launch, they are also advancing their other projects, including Mino-Lok, which targets catheter-related bloodstream infections through innovative antibiotic lock solutions.
Q3 2025 Financial Overview
The financial report for the third quarter highlighted several key figures illustrating Citius' progress:
- Research and development costs totaled $1.6 million, down from $2.8 million compared to the previous year.
- General and administrative expenses were $4.4 million, a reduction from $4.8 million year-over-year.
- The stock-based compensation stood at $2.7 million, compared to $3.1 million during the same quarter last year.
- The net loss for the quarter was approximately $9.2 million, translating to a loss of ($0.80) per share, which is an improvement compared to a net loss of $10.6 million, or ($1.57) per share, a year earlier.
- As of the end of June, Citius had $6.1 million in cash and cash equivalents to sustain operational activities.
Future Prospects
Citius remains committed to optimizing its drug launch strategies while addressing significant market demands. The anticipated financing from upcoming warrant exercises and further capital-raising initiatives will enhance their ability to deliver on their innovative products.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals is dedicated to advancing its pipeline of first-in-class critical care solutions. Their key projects include the recently FDA-approved LYMPHIR™, an immunotherapy for cutaneous T-cell lymphoma, and Mino-Lok®, aimed at tackling infections associated with catheters.
Frequently Asked Questions
What financial results did Citius Pharmaceuticals report?
Citius reported a net loss of $9.2 million for the third quarter, with significant funding raised to support their operations.
What is LYMPHIR™?
LYMPHIR™ is a targeted immunotherapy for cutaneous T-cell lymphoma, set for launch in the upcoming quarter.
How much funding did Citius Pharmaceuticals raise this quarter?
The company raised $12.5 million, with an additional $9 million from Citius Oncology in July.
What are the company’s future plans?
Citius aims to transition to a fully integrated commercial organization while preparing for the launch of LYMPHIR™.
What other products are in development by Citius?
Citius is also working on Mino-Lok®, an innovative solution designed to prevent catheter-related bloodstream infections.
